<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969614</url>
  </required_header>
  <id_info>
    <org_study_id>WestChina-COVID</org_study_id>
    <nct_id>NCT04969614</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients</brief_title>
  <official_title>Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on&#xD;
      transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals&#xD;
      have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response&#xD;
      to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines&#xD;
      in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney&#xD;
      transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>seropositive anti-COVID-19 antibody</measure>
    <time_frame>2 to 6 weeks after the second injection of inactivated vaccine</time_frame>
    <description>seropositive anti-COVID-19 antibody, including IgM, IgG, and IgA</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>kidney transplant recipients</arm_group_label>
    <description>kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients receiving kidney transplantation in West China Hospital between 01/01/2015 and&#xD;
        01/03/2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Receiving kidney transplantation in West China Hospital, Sichuan University&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) History of rejection or infection over the previous 3 months; 2) receiving kidney&#xD;
        transplantation &gt;3 months; 3) Combined with HBV/HVC/HIV infection in the donor or&#xD;
        recipient; 4) Malignancy history in the donor and recipient; 5) organ transplant history in&#xD;
        the recipient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Tao Lin</investigator_full_name>
    <investigator_title>West China Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

